Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exact Sciences ( (EXAS) ) has provided an update.
On November 19, 2025, Exact Sciences agreed to be acquired by Abbott Laboratories, with Exact to become a wholly owned Abbott subsidiary following a planned merger. In January 2026, Exact mailed a definitive proxy statement to shareholders outlining the transaction, including a proposed $105 per share all-cash consideration supported by Centerview Partners’ valuation analyses.
By February 10, 2026, three shareholder lawsuits had been filed in New York alleging that the proxy statement contained false or misleading disclosures or omitted material information, and one action also alleged violations of Wisconsin securities law. While Exact denies the claims and maintains that no additional disclosure is legally required, it has issued supplemental financial and valuation details to reduce litigation risk, avoid delays to the Abbott merger and minimize associated costs and uncertainties for stakeholders.
The most recent analyst rating on (EXAS) stock is a Hold with a $105.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.
Spark’s Take on EXAS Stock
According to Spark, TipRanks’ AI Analyst, EXAS is a Outperform.
Exact Sciences’ stock is bolstered by strong technical momentum and a positive corporate event with the merger announcement. However, profitability challenges and valuation concerns temper the overall score. The earnings call provided a positive outlook, but financial performance remains a critical area for improvement.
To see Spark’s full report on EXAS stock, click here.
More about Exact Sciences
Exact Sciences is a U.S.-based diagnostics company focused on cancer screening and related testing, operating in the broader life sciences and medical diagnostics industry. Its products and services target early detection and management of cancer and other conditions, positioning the company within a high-growth, innovation-driven segment of the healthcare market.
Average Trading Volume: 5,315,930
Technical Sentiment Signal: Buy
Current Market Cap: $19.69B
Learn more about EXAS stock on TipRanks’ Stock Analysis page.